Mood Instability
Cross-source consensus on Mood Instability from 1 sources and 6 claims.
1 sources · 6 claims
Risks & contraindications
Comparisons
Other
Other
Other
Highlighted claims
- Mood instability is the primary outcome of the trial. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Mood instability is assessed using daily smartphone-based self-ratings through the Danish Monsenso system. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Monthly mood instability scores are calculated with root mean square successive difference applied to daily mood ratings. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Mood instability is associated with perceived stress, reduced functioning, reduced quality of life, relapse, and hospitalisation. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Mood instability is increasingly recognised as a core psychopathological feature of bipolar disorder. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- The study treats mood instability as a sensitive patient-centred outcome that may detect clinically relevant change better than relapse or recurrence outcomes. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)